Heart disease treatments have reached a significant milestone as the Food and Drug Administration approves enlicitide, a once-daily tablet designed to lower dangerous cholesterol levels by nearly 60 percent without requiring injections. For decades, cardiovascular disease has remained the leading cause of death across the United States, claiming 694,708 American lives in 2025 alone and outpacing all forms of cancer combined, according to official health data. Globally, the condition accounts for roughly 20 million deaths annually.
Yet public health figures show that the overall enemy is gradually losing ground. The age-adjusted death rate from cardiovascular disease in the United States has dropped by approximately three-quarters since 1950, while deaths specifically caused by heart attacks have fallen 89 percent since 1970. This broader medical progress rests heavily on managing low-density lipoprotein, commonly known as LDL or bad cholesterol.
For generations, high LDL scores proved exceptionally difficult to address through diet and willpower alone. While millions of patients rely on statins to reduce cardiovascular risks, those traditional workhorses frequently cause muscle aches or fail to drive stubborn cholesterol numbers low enough. Enlicitide targets these exact patient populations, offering the potency of injectable PCSK9 inhibitors in an oral tablet taken on an empty stomach.
The Genetic Blueprint Behind Modern Cholesterol Breakthroughs
The scientific path to enlicitide began more than two decades ago at the University of Texas Southwestern. Geneticists Helen Hobbs and Jonathan Cohen investigated why certain individuals naturally maintained remarkably low cholesterol levels by analyzing data from the Dallas Heart Study. Their research identified a small group of participants carrying a broken copy of the PCSK9 gene, which allowed their bodies to clear LDL from the bloodstream with unusual efficiency.
According to findings from that research, carriers of the strongest gene variant exhibited roughly 28 percent lower LDL levels and an 88 percent reduction in heart disease risk compared to non-carriers. That discovery provided pharmaceutical developers with a clear biological target: imitate the protective effects of a naturally occurring genetic mutation. Modern PCSK9 therapies, including the newly approved enlicitide tablet, directly replicate this mechanism.
From Daily Pills to Single-Infusion Gene Editing
While daily oral medications expand treatment options, adherence remains a persistent hurdle in modern cardiology. Clinical data indicates that roughly half of all patients prescribed statins stop taking them within the first year. Addressing this adherence gap has prompted researchers to explore permanent genetic interventions.
Verve Therapeutics, a biotechnology firm now owned by Eli Lilly, has evaluated a novel treatment that introduces a single-letter edit to the PCSK9 gene in the liver via a single infusion. Early human trials published in the New England Journal of Medicine demonstrated that one dose successfully reduced LDL levels by up to 62 percent and sustained that reduction for over a year by effectively switching off the target gene.
Beyond cholesterol management, broader public health trends have contributed to declining cardiovascular mortality. Smoking rates among U.S. adults have dropped from roughly 40 percent in the 1960s to under 15 percent. Meanwhile, advancements in generic medications have improved the early detection and management of high blood pressure, a condition that previously lacked effective treatments during the mid-20th century.
Anti-obesity medications such as GLP-1 receptor agonists are also reshaping preventative cardiology. More than one in ten American adults currently use anti-obesity drugs, and major clinical trials have shown that treatments like semaglutide can reduce major adverse cardiovascular events by 20 percent.
Access and Evolving Patient Demographics
Despite these pharmacological advancements, healthcare systems face new challenges in cardiovascular care. While heart attack mortality has plummeted, deaths from other cardiac conditions—such as heart failure, arrhythmias, and hypertensive disease—have risen 81 percent since 1970. Public health experts note that this upward shift partly reflects medical success: patients who survive initial heart attacks now live long enough for their hearts to wear out from other complications.
At the same time, rising obesity rates—affecting approximately 40 percent of U.S. adults—continue to drive up diagnoses of diabetes and hypertension. Economic access remains another critical barrier to widespread prevention. Enlicitide launches at an approximate cost of $300 per month, with insurance coverage varying widely among providers, while upcoming gene-editing therapies are projected to debut at significantly higher price points.
With more than 60 percent of U.S. adults projected to develop some form of cardiovascular disease over their lifetime, the ultimate impact of these therapies depends heavily on broad, equitable patient access. Medical researchers and regulatory agencies continue to monitor long-term outcomes data as these next-generation treatments move into clinical practice.
Related reading